

Maria C Kjellsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8871668/publications.pdf>

Version: 2024-02-01

40
papers

593
citations

687363

13
h-index

642732

23
g-index

40
all docs

40
docs citations

40
times ranked

971
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Obesity on Postprandial Triglyceride Contribution to Glucose Homeostasis, Assessed with a Semimechanistic Model. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 112-124.	4.7	2
2	A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 416-423.	4.7	6
3	Optimal Designs for Model-Based Assessment of Insulin Sensitivity and Glucose Effectiveness. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 116-124.	2.0	0
4	An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales. <i>AAPS Journal</i> , 2021, 23, 45.	4.4	1
5	Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 815-823.	1.8	1
6	Postprandial triglyceride reduction following acute treatment of a selective 5-hydroxytryptamine _{2c} agonist and characterization using a semi-physiological model. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1001-1010.	4.4	1
7	Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data. <i>AAPS Journal</i> , 2021, 23, 9.	4.4	2
8	Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 238-245.	4.7	6
9	Sweet/Fat Preference Taste in Subjects Who are Lean, Obese and Very Obese. <i>Pharmaceutical Research</i> , 2020, 37, 244.	3.5	5
10	A Bounded Integer Model for Rating and Composite Scale Data. <i>AAPS Journal</i> , 2019, 21, 74.	4.4	15
11	The integrated glucose insulin minimal model: An improved version. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 7-19.	4.0	7
12	Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 105-114.	2.5	5
13	Semi-physiological model of postprandial triglyceride response in lean, obese and very obese individuals after a high-fat meal. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 660-666.	4.4	3
14	Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. <i>Clinical Pharmacokinetics</i> , 2018, 57, 591-599.	3.5	26
15	Model-Based Residual Post-Processing for Residual Model Identification. <i>AAPS Journal</i> , 2018, 20, 81.	4.4	6
16	Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 331-341.	2.5	2
17	Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 432-441.	2.5	5
18	Impact of demographics and disease progression on the relationship between glucose and HbA1c. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 104, 417-423.	4.0	5

#	ARTICLE	IF	CITATIONS
19	Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 686-694.	2.5	1
20	Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide following Ingestion of Glucose. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 290-297.	2.5	8
21	Model-Based Interspecies Scaling of Glucose Homeostasis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 778-786.	2.5	17
22	Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 340-348.	2.0	14
23	Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach. <i>Drug Metabolism and Disposition</i> , 2016, 44, 505-516.	3.3	43
24	Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1613-1624.	2.4	5
25	Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats. <i>AAPS Journal</i> , 2016, 18, 1203-1212.	4.4	15
26	Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes. <i>Interface Focus</i> , 2016, 6, 20150075.	3.0	21
27	Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use it. <i>BMC Systems Biology</i> , 2015, 9, 52.	3.0	40
28	Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 809-817.	2.0	15
29	Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 1-10.	1.8	16
30	A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 589-600.	2.0	19
31	Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 446-457.	3.2	154
32	Good Penetration of Moxifloxacin into Human Abscesses. <i>Pharmacology</i> , 2012, 90, 146-150.	2.2	4
33	Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1419-1423.	1.9	0
34	Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models. <i>Pharmaceutical Research</i> , 2011, 28, 2610-2627.	3.5	12
35	Evaluation of the nonparametric estimation method in NONMEM VI. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 37, 27-35.	4.0	9
36	The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 81-99.	1.8	22

#	ARTICLE	IF	CITATIONS
37	Comparison of proportional and differential odds models for mixed-effects analysis of categorical data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2008, 35, 483-501.	1.8	19
38	The back-step method—Method for obtaining unbiased population parameter estimates for ordered categorical data. <i>AAPS Journal</i> , 2004, 6, 13-22.	4.4	4
39	Estimating Bias in Population Parameters for Some Models for Repeated Measures Ordinal Data Using NONMEM and NL MIXED. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2004, 31, 299-320.	1.8	17
40	The effects of dose staggering on metabolic drug—drug interactions. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 20, 223-232.	4.0	40